The endocannabinoid system may offer new approaches to managing endometriosis pain
A review of the complex pain mechanisms in endometriosis identified the endocannabinoid system as a relevant pharmacological target, given its involvement in multiple pain pathways affected by the condition.
Quick Facts
What This Study Found
Endometriosis causes diffuse and poorly localized severe pain that is often inadequately managed by current medical, hormonal, and surgical approaches. The review described how endometriosis involves multiple overlapping pain mechanisms: inflammatory, neuropathic, and central sensitization.
The endocannabinoid system (ECS) intersects with several of these pain pathways. The review presented current data and theories about how modulating the ECS could target different aspects of endometriosis-associated pain, including the inflammatory component, nerve growth into endometrial lesions, and altered pain processing in the central nervous system.
Key Numbers
Endometriosis affects an estimated 10% of reproductive-age women. Current medical management has high recurrence rates. The review identified the ECS as relevant to inflammatory, neuropathic, and central sensitization pain mechanisms in endometriosis.
How They Did This
Computerized literature search combining keywords "endometriosis," "endocannabinoid," "cannabinoid receptor," "THC," and "pain mechanisms." The review synthesized findings on pain mechanisms in endometriosis and evidence for ECS involvement.
Why This Research Matters
Endometriosis affects roughly 10% of reproductive-age women and current pain management often fails. The endocannabinoid system represents a biologically plausible new target because it is involved in pain modulation, inflammation, and immune regulation, all of which are disrupted in endometriosis.
The Bigger Picture
The intersection of the endocannabinoid system with multiple endometriosis pain pathways explains why some patients report symptom relief from cannabis, even though no controlled clinical trials had been conducted at the time of this review. Understanding which specific pain mechanisms the ECS targets could guide the development of more precise cannabinoid-based therapies.
What This Study Doesn't Tell Us
This is a narrative review without systematic methodology. The evidence linking the ECS to endometriosis pain is largely theoretical and based on preclinical data. No clinical trials of cannabinoid treatments for endometriosis were included. The review does not address potential risks of cannabinoid use.
Questions This Raises
- ?Would THC, CBD, or other cannabinoids be most effective for endometriosis pain?
- ?Could endocannabinoid-modulating drugs reduce the need for surgical intervention?
- ?Is the endocannabinoid system actually dysregulated in endometriosis tissue?
Trust & Context
- Key Stat:
- The endocannabinoid system intersects with inflammatory, neuropathic, and central sensitization pathways in endometriosis
- Evidence Grade:
- Narrative review presenting theoretical rationale and preclinical evidence. No clinical trial data on cannabinoids for endometriosis was available.
- Study Age:
- Published in 2017. Clinical research on cannabinoids for endometriosis has since begun, with several studies exploring patient-reported outcomes.
- Original Title:
- The Clinical Significance of Endocannabinoids in Endometriosis Pain Management.
- Published In:
- Cannabis and cannabinoid research, 2(1), 72-80 (2017)
- Database ID:
- RTHC-01341
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis treat endometriosis pain?
The review provides a theoretical basis for why cannabinoids might help, given the endocannabinoid system's involvement in the pain pathways affected by endometriosis. However, no controlled clinical trials existed at the time of publication. Anecdotal reports from patients are encouraging but not yet supported by rigorous evidence.
Why is endometriosis pain so hard to treat?
Endometriosis pain involves multiple overlapping mechanisms including inflammation, nerve growth into lesions, and changes in how the central nervous system processes pain. Current treatments often address only one mechanism, which may explain why they frequently fail.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01341APA
Bouaziz, Jerome; Bar On, Alexandra; Seidman, Daniel S; Soriano, David. (2017). The Clinical Significance of Endocannabinoids in Endometriosis Pain Management.. Cannabis and cannabinoid research, 2(1), 72-80. https://doi.org/10.1089/can.2016.0035
MLA
Bouaziz, Jerome, et al. "The Clinical Significance of Endocannabinoids in Endometriosis Pain Management.." Cannabis and cannabinoid research, 2017. https://doi.org/10.1089/can.2016.0035
RethinkTHC
RethinkTHC Research Database. "The Clinical Significance of Endocannabinoids in Endometrios..." RTHC-01341. Retrieved from https://rethinkthc.com/research/bouaziz-2017-the-clinical-significance-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.